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Introduction {#prp2285-sec-0001}
============

Effective leukemia therapy is hampered by drug resistance, which is a serious problem that results from various mechanisms. Pediatric leukemia patients with cancer cells that show resistance to antileukemic agents in vitro have a more dismal prognosis than patients with drug‐sensitive leukemia cells (Holleman et al. [2004](#prp2285-bib-0007){ref-type="ref"}). The pattern of gene expression in leukemia cells with acquired resistance to standard therapy is probably substantially different compared to leukemia cells prior to the initiation of treatment because drug‐resistant subpopulations grow selectively as treatment progresses. Nevertheless, how cells acquire drug resistance is unclear. Many signaling pathways and genes that may affect the response of leukemia cells to therapy have been identified. Because many factors are involved in the mechanism of acquisition of drug resistance, the "one gene: one outcome" hypothesis cannot adequately explain acquired resistance in leukemia (Glasspool et al. [2006](#prp2285-bib-0004){ref-type="ref"}). Thus, multiple mechanisms and multiple genes rather than a single pathway or gene likely mediate acquired resistance.

Aberrant methylation, including genome‐wide hypomethylation and regional hypermethylation of promoters for genes such as tumor suppressors, is one mechanism of tumorigenesis (Eden et al. [2003](#prp2285-bib-0003){ref-type="ref"}). Methylation of eukaryotic DNA occurs at CpG‐enriched promoters. Such epigenetic changes are critically involved in acquisition of drug resistance, which is mediated by changes in gene expression that occur following chemotherapy but that are not caused by genetic mutations. Wei et al. ([2003](#prp2285-bib-0017){ref-type="ref"}) used drug‐resistant cell lines and differential methylation hybridization and showed many differences in CpG island methylation and epigenetic regulation after drug treatment. However, this group did not determine which genes were aberrantly methylated in resistant cells. In general, recent studies including ours have investigated only a few CpG island markers in methylation‐related drug resistance (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}).

3′‐deamino‐3′‐morpholino‐13‐deoxo‐10‐hydroxycarminomycin hydrochloride, also known as KRN 8602 (MX2), is a new morpholino anthracycline derivative that acts as a topoisomerase (Topo) II*α* inhibitor and is cytotoxic to tumor cells (Watanabe et al. [1988](#prp2285-bib-0015){ref-type="ref"}). MX2 is highly lipophilic and easily passes through the cell membrane in a P‐glycoprotein‐independent manner (Watanabe et al. [1988](#prp2285-bib-0015){ref-type="ref"}). The antitumor effects of MX2 are superior to those of adriamycin (ADR). MX2 is toxic to mouse and human tumor cell lines as well as multidrug‐resistant tumor cell lines that express high levels of P‐glycoprotein (Watanabe et al. [1991](#prp2285-bib-0016){ref-type="ref"}). MX2 may thus be useful for eradicating multidrug‐resistant tumors. By continuously exposing cells grown in suspension to increasing amounts of MX2, we previously established the MX2‐resistant human myelogenous leukemia cell line K562/MX2, which is derived from the parent cell line K562/P (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}). K562/MX2 cells show lower levels of Topo II*α* mRNA and protein, and the Topo II*α* gene in these cells is aberrantly methylated at CpG islands. Thus, drug resistance in K562/MX2 cells may be due to aberrant methylation (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}). We therefore next investigated the relationship between global gene expression and methylation in drug‐resistant cells and identified genes that confer resistance. High‐throughput methylation analysis of multiple CpG sites can be performed with the GoldenGate Methylation BeadArray (Illumina Inc. Tokyo, Japan) (Ang et al. [2010](#prp2285-bib-0001){ref-type="ref"}). Here, we evaluated the genome‐wide methylation status using the methyl array, compared gene expression profiles using microarray, and analyzed the entire profile of altered gene expression with methylation using Gene Ontology (GO) analysis. We found that resistant cells were hypermethylated in whole genes, and that genes involved in gene silencing and the immunological response were most critical for methylation‐related altered gene expression. In addition, using key node analysis, p38*α* mitogen‐activated protein kinase (MAPK) was identified as a novel enzyme that may mediate MX2‐related resistance. In addition to the K562 cell line, we also established a lymphoblastic leukemia cell line with resistance to MX2 (BALL/MX2). Compared to sensitive cells, p38 kinase activity in both resistant cell lines was increased. Blocking p38 kinase activity and phosphorylated p38*α* protein with SB203580 or SB20190, which are specific inhibitors of p38 MAPK, or using siRNA to knock down p38*α* mRNA expression, restored the sensitivity to MX2 in resistant cells, concomitant with decreased expression of p38*α* mRNA, phosphorylated protein, and kinase activity.

Materials and Methods {#prp2285-sec-0002}
=====================

Reagents {#prp2285-sec-0003}
--------

We used the hydrochloride form of MX2 (Watanabe et al. [1988](#prp2285-bib-0015){ref-type="ref"}, [1991](#prp2285-bib-0016){ref-type="ref"}). ADR, etoposide, vincristine, and dimethyl sulfoxide, were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Phosphate‐buffered saline without metal salt solution (PBS (−)) was purchased from Nissui (Tokyo, Japan). RPMI 1640, Hanks\' balanced salt solution without Ca^2+^ or Mg^2+^ (HBSS), fetal calf serum, and gentamicin were purchased from Life Technologies, Inc. (Gaithersburg, MD). 5‐Aza‐2′‐deoxycytidine was purchased from Sigma Aldrich Japan (Tokyo, Japan). SB203580 (4‐(4‐fluorophenyl)‐2‐(4‐methylsulfinylphenyl)‐5‐(4‐pyridyl)1H‐imidazole) and SB202190 (4‐(4‐fluorophenyl)‐2‐(4‐hydroxyphenyl)‐5‐(4‐pyridyl)1H‐imidazole), which are p38 MAPK inhibitors, and SB202474 (4‐Ethyl‐2(p‐methoxyphenyl)‐5‐(4′‐pyridyl)‐IH‐imidazole), which is a negative control, were purchased from Calbiochem (Tokyo, Japan). siRNAs were obtained from Ambion (Carlsbad, CA).

Cell lines {#prp2285-sec-0004}
----------

Parental cell lines (K562/P, human myelogenous leukemia and BALL‐1, human B‐cell lymphoblastic leukemia) were purchased from RIKEN (Tsukuba, Japan). BALL‐1 (BALL) cell line is established from typical human B‐cell leukemia (male) (Miyoshi et al. [1977](#prp2285-bib-0009){ref-type="ref"}). K562 cell line is established from pleural effusion with chronic myelogenous leukemia of 53 years old female, which is sensitive to NK cell and can differentiate to erythroid cells (Lozzio and Lozzio [1975](#prp2285-bib-0008){ref-type="ref"}). The MX2‐resistant cell line was established with limiting dilution using continuous exposure to increasing amounts of MX2 (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}). MX2‐resistant cells were cultured in the absence of MX2 for 2 weeks before use in experiments. The MycoAlert^TM^ mycoplasma detection kit (Lonza Walkersville Inc., Tokyo, Japan) was used to confirm the absence of *Mycoplasma* organisms in all cell lines.

Cytotoxicity assay {#prp2285-sec-0005}
------------------

The MTT assay (CellTiter96 AQueaus One solution Cell Proliferation Assay, Promega Corp., Madison, WI) or trypan blue exclusion was used to determine cytotoxicity (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}). Briefly, 1 × 10^5^ cells/mL were incubated with various concentrations of MX2, etoposide, ADR, or vincristine for 72 h. Viable cells were counted after performing the MTT assay or trypan blue staining. The combination index method (Zhao et al. [2004](#prp2285-bib-0022){ref-type="ref"}) was used to determine the synergistic effect of inhibitors and siRNAs plus MX2.

5‐Aza‐2′‐deoxycytidine treatment {#prp2285-sec-0006}
--------------------------------

Briefly, 1 × 10^5^ cells/mL (total 1 × 10^7^ cells) were grown for 72 h in a medium that included 10 *μ*mol/L 5‐Aza‐2′‐deoxycytidine. Fresh medium and drug were replaced daily.

Isolation of genomic DNA and quality assessment {#prp2285-sec-0007}
-----------------------------------------------

DNA was extracted from freshly harvested cells with the QIAamp DNA Mini Kit (Qiagen, Tokyo, Japan). Low‐percentage (0.5%) agarose gel electrophoresis and low‐power voltage were used to assess the quality of the extracted DNA. Genomic DNA was of sufficient quality when a high molecular weight band (\<40 kb) was visible and when no strong low molecular weight band (\<2.0 kb) was visible on the gel after 3 hours of electrophoresis. Alternatively, an OD260/280 between 1.8 and 2.0 indicated DNA of sufficient quality.

Bisulphite conversion {#prp2285-sec-0008}
---------------------

The EZ DNA methylation kit (Zymo Research, Irvine, CA) was used for bisulphite conversion of genomic DNA with modifications for the Illumina Infinium Methylation Assay (Illumina, Tokyo, Japan). Briefly, 1 *μ*g genomic DNA was incubated with 5 *μ*L M‐Dilution buffer at 37°C for 15 min. Then, 100 *μ*L CT conversion reagent was prepared as described by the manufacturer and added to the mixture, which was incubated in a thermal cycler for 16 cycles at 95°C for 30 sec and 50°C for 60 sec. Aliquots of bisulphite‐converted DNA were added to 96‐column plates provided in the kit, and then desulphonated and purified as described by the manufacturer. These samples were used immediately for chip analysis, as described below.

Illumina infinium human methylation27 beadchip {#prp2285-sec-0009}
----------------------------------------------

The Illumina Infinium Human Methylation27 BeadChip Kit was used for assays with bisulphite‐converted genomic DNA. This beadchip includes 27,578 CpG loci in \>14,000 human RefSeq genes at single‐nucleotide resolution. The reagents included in the kit were used for chip processing and analysis of data. Briefly, 4 *μ*L bisulphite‐converted genomic DNA was denatured in 0.014 N sodium hydroxide and neutralized. DNA was then amplified using components included in the kit for 20--24 h at 37°C. After fragmentation, 12 *μ*L of each sample was loaded onto a 12‐sample chip, which was inserted into a hybridization chamber as described by the manufacturer. Samples were incubated at 48°C for 16--20 h, chips were washed with wash buffers from the kit, and then chips were incubated in a fluid flow‐through station for primer extension and stained using components provided in the kit. The iScan scanner (Illumina) was used for image processing of polymer‐coated chips. We used a cutoff level for detection of a *P* \< 0.001, which is the most stringent criterion in the Illumina GoldenGate Methylation array. BeadStudio v3.0 software (Illumina) was used for data extraction. Methylation values for each CpG locus were expressed as a *β*‐value, which is a continuous value from 0 (completely unmethylated) to 1 (completely methylated) and is based on the following equation: *β*‐value = (signal intensity of methylation‐detection probe)/(signal intensity of methylation‐detection probe + signal intensity of non methylation detection probe). In accordance with the manufacturer\'s recommendation, results \>0.15 as determined by the difference in the *β*‐value between two sets of groups were considered significant.

RNA isolation, real‐time PCR, and microarray analysis {#prp2285-sec-0010}
-----------------------------------------------------

The Qiagen RNA Mini kit (Qiagen) was used for isolation of total RNA from each sample, and RNA integrity was confirmed following 1% agarose gel electrophoresis. Real‐time PCR analysis was performed as described (Yamanishi et al. [2015](#prp2285-bib-0020){ref-type="ref"}) using the following primers: p38*α* sense: 5′‐TGCCCGAGCGTTACCAGACC‐3′ and antisense: 5′‐CTGTAAGCTTCTGACATTTC‐3′. The Agilent Low RNA Input Fluorescent Linear Amplification kit (Agilent Technologies, Tokyo, Japan) was used for in vitro transcription in the presence of Cy3‐ and Cy5‐CTP. Next, 825 ng‐labeled complementary RNA from each pair was purified separately, combined, mixed with hybridization buffer prepared using the In Situ Hybridization Plus kit (Agilent Technologies), and added to the microarray. Samples were hybridized to an Agilent 4 × 44k Whole Human Genome microarray (G4112F; Agilent Technologies), which contains 43,376 coding and noncoding sequences from the human genome, in an Agilent G2545A hybridization oven. Hybridization and washing conditions were as described by the manufacturer in the protocol for oligonucleotide microarray hybridization (Agilent Technologies). Feature Extraction software (version 9.3; Agilent Technologies) and Spotfire software (version 8.0; Spotfire, Cambridge, MA) were used to analyze data from the Agilent G52565BA microarray scanner. Fluorescent spots on the microarrays were considered present or absent. Automatic recognition software (Feature Extraction version 9.3; Agilent Technologies) selected transcripts that were considered present, and quantile normalization was used to normalize data. Spots that failed quality control procedures (those with signal intensity \<1.0) were excluded from additional analysis. The possibility of dye‐related bias in the microarray results was excluded with an algorithm included in the software that applied normalization factors (linear and lowness normalization). Data were imported into Excel files (Microsoft, Redmond, WA) for subsequent data and statistical analysis (Agilent Technologies provides details of these procedures).

Integration of methyl array data and expression array data {#prp2285-sec-0011}
----------------------------------------------------------

After quantile normalization, we integrated the data from the methyl array and expression array to identify genes that were strongly related to methylation‐specific altered expression. We considered increased methylation as a difference in the *β*‐value of \>0.15, decreased methylation as a difference in the *β*‐value of \<0.15, increased expression as \>1.5‐fold of the expression level, and decreased expression as \<1‐ to 1.5‐fold of the expression level.

GO analysis {#prp2285-sec-0012}
-----------

Functional class scoring analysis based on Biobase Knowledge Library manual curation was used to determine GO classes that were differentially methylated in drug‐sensitive compared to drug‐resistant cells. A *P* value for comparison of drug‐sensitive and ‐resistant cells was computed for each gene in a GO class. Multiple testing corrections with the Benjamini and Hochberg false discovery rate (FDR) (Reiner‐Benaim [2007](#prp2285-bib-0012){ref-type="ref"}) were used to determine the set of *P* values for a GO class.

Key node search algorithm {#prp2285-sec-0013}
-------------------------

The search for signaling molecules (key nodes) in the network vicinity of a gene list can be performed based on only one gene list, or based on a primary gene list with an additional gene list as a secondary set. Genes in the secondary set were incorporated such that the key node algorithm goes through the elements of this gene set. The network path was attracted by the secondary genes, resulting in longer paths that are often cheaper than shorter paths if they include molecules from the secondary set. The algorithm is a feed‐forward‐based approach that transforms the original weights of the network into new weights. The weights of the resulting network reflect the desired attraction power.

Score: The significance score, used for ranking the key node results, counted the hits that were relative to the respective logarithmized volume *Vi* that was required to reach every hit.

Equation 1. Score calculation$$S = N_{0} + \sum\limits_{i = 1}^{r}\frac{N_{i} - N_{i - 1}}{1 + \log(V_{i})}$$

Volume *V* ~*i*~ = number of total compounds reachable from the key node within a distance.

Hits *N* ~*i*~ = number of targets reached by key node k within distance *i*.

With increasing distance *i*, the volume *V* ~*i*~ also increases. The maximum distance is limited by *r*.

### FDR {#prp2285-sec-0014}

Each individual key node was assigned an FDR value, which represents the probability that the observed rank or higher ranks was occupied by random chance and was estimated on‐the‐fly by random sampling. The ranking of the key nodes was defined by sorting them according to the score described above in descending order. All key nodes with an observed rank \<200 were assigned an FDR value of 1.0 by definition, because their score was considered insufficient. Molecules with no hits were assigned the last rank because the score was 0 in this case.

### *Z*‐score {#prp2285-sec-0015}

In addition to the FDR, each key node was assigned a *Z*‐score, which measures the deviation of the observed rank of the key node from the expected rank in a random case. The *Z*‐score was divided by the standard deviation.

Equation 2. Z‐score calculation$$Z = \frac{X - \mathit{\mu}}{\mathit{\sigma}\mathit{\mu}\mathit{\varepsilon}^{-}}$$

In this formula, the rank distribution was assumed to comply with normal distribution. Key nodes with a *Z*‐score \>1.0 were considered significant.

Promoter analysis was performed using the online tool ExPlain 3.1 (<http://explain.biobase-international.com/>) for detection of overrepresented transcription factor‐binding sites (Stegmaier et al. [2011](#prp2285-bib-0013){ref-type="ref"}; Zawacka‐Pankau et al. [2011](#prp2285-bib-0021){ref-type="ref"}; Takahashi et al. [2015](#prp2285-bib-0014){ref-type="ref"}). For the analysis, we selected regions from 1000‐bp upstream to 100‐bp downstream of the transcription start site of each gene of absolute fold change \>4 (Yes set) and \<1.12 (No set). The vertebrate_h0.01 set of transcription factors matrix from the TRANSFAC database was used for scanning potential binding sites. We used all promoters of genes with *P* \< 0.01. The high‐specific matrices with a Yes/No score \>2.1, *P* \< 0.05, and matched promoters *P* \< 0.05 were selected with cutoffs from minSUM. The upstream analysis was performed with distance threshold value of 6 and FDR \< 0.05 including expression/transregulation reaction and following curated chains.

Western blot analysis {#prp2285-sec-0016}
---------------------

Cells were lysed in RIPA buffer (WAKO Pure Chemical Industries Ltd.) with proteinase (Sigma Aldrich) and phosphatase inhibitors or in 1× Laemmli buffer, and lysates were separated on a SDS‐PAGE gel. After transfer to membranes, blots were incubated with primary antibodies against phosphorylated p38*α* (Cell Signaling Technology, Inc., Danvers, MA) and GAPDH (Wako).

p38 kinase assay {#prp2285-sec-0017}
----------------

The CycLex p38 Kinase Assay kit (CycLex Co., Ltd., Nagano, Japan) was used for the p38 kinase assay.

Transfection of siRNA {#prp2285-sec-0018}
---------------------

siRNAs that were used to knock down p38*α* expression and the corresponding negative control siRNA were purchased from Ambion (Tokyo, Japan). Cells (3 × 10^3^ cells/well) were plated in 96‐well plates and incubated for 24 h. Cells were then transfected with 5 pmol control or p38*α* siRNA using Lipofectamine Plus transfection reagent (Life Technologies, Tokyo, Japan). Twenty‐four hours post transfection, the treated cells were incubated with various concentrations of MX2 for 72 h and measured cytotoxicity. For confirming to knock down p38*α* expression, mRNA were extracted 24 h after transfection, and protein were extracted 96 h after transfection. To establish 100% survival, cells were incubated with vehicle containing Hiperfect alone. Assays were performed in triplicate, and at least three independent experiments were conducted for each condition.

Methylation‐specific polymerase chain reaction analysis for p38*α* {#prp2285-sec-0019}
------------------------------------------------------------------

For MSP analysis, genomic DNA was obtained and 300 ng of DNA per sample was treated as described before (Yamanishi et al. [2015](#prp2285-bib-0020){ref-type="ref"}). Primer pairs for MSP of p38*α* (*Homo sapiens* mitogen‐activated protein kinase 14 (MAPK14) gene, GenBank: EU332860.1) were designed based on methylated and unmethylated DNA sequences in the promoter region, as follows: p38*α*1M; pos. 1951‐2059: 5′‐TATATTGGGTAAAATTTCGGTTTTC‐3′, 5′‐AATACTCCCGTTCCAACTACTACG‐3′, and p38*α*1U; 5′‐ TATATTGGGTAAAATTTTGGTTTTTG‐3′, 5′‐ATACTCCCATTCCAACTACTACACC‐3′. p38*α*2M; pos. 4618‐4738: 5′‐GTCGGGTGTAGTGGTTTACGT‐3′, 5′‐TTTAATAAAAACGAAATTTCACCG‐3′, and p38*α*2U; 5′‐GGTTGGGTGTAGTGGTTTATGT‐3′, 5′‐TTAATAAAAACAAAATTTCACCATA‐3′. p38*α*3M; pos. 10992‐11210: 5′‐TTTAGTTTGGAGTGTAGTGGTACGA‐3′, 5′‐ AAAAACCGAAACAAAAAAATCG‐3′, and p38*α*3U; 5′‐ TTTAGTTTGGAGTGTAGTGGTATGA‐3′, 5′‐AAAAAACCAAAACAAAAAAATCACT‐3′. p38a4M; pos. 13929‐14207: 5′‐GTTTAGGTTGGGTGTAGTGGTTTAC‐3′, 5′‐TAAAACTAAATCTTACTCTATCGCC‐3′, and p38*α*4U; 5′‐TTAGGTTGGGTGTAGTGGTTTATGT‐3′, 5′‐TTTTAAAACTAAATCTTACTCTATCACC‐3′. Polymerase chain reaction was performed using the EpiScope MSP kit (Takara Biotechnology Company, Ohtsu, Japan) and the ABI Prism 7500 sequence detection system (Applied Biosystems). Amplification was performed with an initial denaturation at 95°C for 30 sec, 45 cycles of denaturation at 98°C for 5 sec, annealing at 55°C for 30 sec, and extension at 72°C for 60 sec. Subsequently, melting curve analysis was performed on PCR products.

Apoptosis assay {#prp2285-sec-0020}
---------------

Caspase 3/7 activity assays were determined using Caspase‐Glo 3/7 assay according to the manufacturer\'s instructions in 96‐well plates (Promega, Madison, WI). We used 10 *μ*mol/L SB202190, 10 *μ*mol/L SB203580, and 10 *μ*mol/L SB202474 as a pretreatment for 30 min. Then, 2.5 nmol/L of MX2 were added, and the cells were cultured for 1 h and performed caspase 3/7 activity assays.

Statistical analysis {#prp2285-sec-0021}
--------------------

The Kruskal--Wallis *H* test was used for statistical analysis. When a significant difference was detected, we used the Mann--Whitney *U* test to calculate the significance of differences between each group. Bonferroni--Dunn correction was performed with uncorrected *P* values by multiplying them by the number of comparisons.

Results {#prp2285-sec-0022}
=======

Establishment and features of the MX2‐resistant cell line {#prp2285-sec-0023}
---------------------------------------------------------

MX2‐resistant cells were established with constant treatment of MX2‐sensitive cells with increasing concentrations of MX2. This subculture of MX2‐resistant cells is grown in the continuous presence of 100 nmol/L or 200 nmol/L MX2, but the phenotype remains stable after growth in medium without MX2 for more than 6 months. MX2‐resistant K562 cells (K562/MX2 cells) were resistant to both MX2 and ADR and also exhibited cross‐resistance to etoposide (Table [1](#prp2285-tbl-0001){ref-type="table-wrap"}).

###### 

IC50 values for MX2, etoposide, adriamycin, and vincristine with or without 5‐Aza‐2′‐deoxycytidine (5AZ) treatment

                              MX2 (nM)                                         Etoposide (nM)                                  Adriamycin (nM)                                  Vincristine (nM)   Carboplatin (*μ*M)
  --------------------------- ------------------------------------------------ ----------------------------------------------- ------------------------------------------------ ------------------ --------------------
  K562/P                      30 ± 4                                           10 ± 4                                          20 ± 3                                           2.0 ± 2.1          20 ± 5.1
  K562/P with 10 *μ*M 5AZ     29 ± 6                                           7 ± 4                                           15.0 ± 11.0                                      1.8 ± 2.9          22 ± 4.8
  K562/MX2                    200 ± 23[a](#prp2285-note-0004){ref-type="fn"}   94 ± 15[a](#prp2285-note-0004){ref-type="fn"}   150 ± 20[a](#prp2285-note-0004){ref-type="fn"}   2.3 ± 1.8          18 ± 6.0
  K562/MX2 with 10 *μ*M 5AZ   46 ± 9[b](#prp2285-note-0005){ref-type="fn"}     8 ± 5[b](#prp2285-note-0005){ref-type="fn"}     130 ± 10.7                                       2.0 ± 1.0          20.5 ± 4.8

The IC50 values were calculated from the cytotoxicity of various drugs.

Data are reported as the mean ± standard deviation from five independent experiments.

*P* \< 0.05, Cytotoxicity in K562/P versus K562/MX2 cells.

*P* \< 0.05, Cytotoxicity in K562 cells with versus without 5‐Aza‐2′‐deoxycytidine treatment.
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DNA methylation patterns in drug‐sensitive and ‐resistant leukemia cells {#prp2285-sec-0024}
------------------------------------------------------------------------

The DNA methylation pattern was clearly different in drug‐sensitive and ‐resistant leukemia cells. After filtering, 19,663 genes were eligible for statistical analysis. Significant results were determined by a difference in the *β* \> 0.15 between the two sets of groups. This analysis identified 4184 genes as differentially expressed between MX2‐sensitive and ‐resistant leukemic cells. Of these, 3229 were hypermethylated, and 955 were hypomethylated in drug‐resistant leukemia cells compared with the same genes in the parent cells (Tables [2](#prp2285-tbl-0002){ref-type="table-wrap"}, [3](#prp2285-tbl-0003){ref-type="table-wrap"} Table S1). Lists of all expression profiles including full gene names and gene accession numbers are shown in Table S1. 5‐Aza‐2′‐deoxycytidine treatment produced slight changes in methylation values on hypermethylated genes in K562/MX2 cells (Table [2](#prp2285-tbl-0002){ref-type="table-wrap"}), but no effect on hypermethylated genes in K562/P cells (Table [3](#prp2285-tbl-0003){ref-type="table-wrap"}).

###### 

Methylation profile in K562/MX2 cells and K562/P cells. List of 30 highly methylated genes in K562/MX2 cells compared to K562/P cells

  Gene symbol   Difference KMX(−)‐P(−)   KMX(−). Beta   P(−). Beta   KMX(+). Beta   P(+). Beta   Description                                                          GenBank accession
  ------------- ------------------------ -------------- ------------ -------------- ------------ -------------------------------------------------------------------- -------------------
  *LOC63928*    0.9727                   0.9848         0.0121       0.9471         0.0096       Hepatocellular carcinoma antigen gene 520                            NM_022097.1
  *FLJ36046*    0.9391                   0.9696         0.0305       0.8823         0.0207       Hypothetical protein LOC164592                                       NM_152612.2
  *TSC22D3*     0.9389                   0.9667         0.0278       0.9247         0.0253       TSC22 domain family; member 3 isoform 2                              NM_004089.3
  *TMEM22*      0.9357                   0.9797         0.0439       0.9712         0.0209       Transmembrane protein 22                                             NM_025246.1
  *HMHA1*       0.9338                   0.9662         0.0324       0.9516         0.0340       Minor histocompatibility antigen HA‐1                                NM_012292.2
  *PLXND1*      0.9304                   0.9487         0.0183       0.8712         0.0108       Plexin D1                                                            NM_015103.1
  *SLC25A22*    0.9266                   0.9539         0.0274       0.8998         0.0199       Mitochondrial glutamate carrier 1                                    NM_024698.4
  *FHIT*        0.9205                   0.9446         0.0241       0.9417         0.0185       Fragile histidine triad gene                                         NM_002012.1
  *RGL3*        0.9184                   0.9627         0.0443       0.9448         0.0419       Ral guanine nucleotide dissociation stimulator‐like 3 isoform 2      XM_934610.1
  *RASL10B*     0.9154                   0.9406         0.0252       0.8588         0.0170       RAS‐like; family 10; member B                                        NM_033315.2
  *RHCG*        0.9143                   0.9273         0.0130       0.8476         0.0201       Rhesus blood group; C glycoprotein                                   NM_016321.1
  *CRIP3*       0.9143                   0.9587         0.0444       0.9346         0.0370       Cysteine‐rich protein 3                                              NM_206922.1
  *NPB*         0.9095                   0.9386         0.0291       0.8942         0.0273       Preproneuropeptide B                                                 NM_148896.2
  *H2AFY2*      0.9072                   0.9504         0.0432       0.9387         0.2239       Core histone macroH2A2.2                                             NM_018649.1
  *GRIN2D*      0.9062                   0.9437         0.0375       0.8909         0.0487       *N*‐methyl‐[d]{.smallcaps}‐aspartate receptor subunit 2D precursor   NM_000836.1
  *ARHGAP4*     0.8988                   0.9757         0.0770       0.9623         0.0383       Rho GTPase‐activating protein 4                                      NM_001666.2
  *DRD1IP*      0.8950                   0.9254         0.0304       0.8854         0.0422       Dopamine receptor D1 interacting protein                             NM_015722.2
  *SYK*         0.8930                   0.9656         0.0727       0.9392         0.0451       Spleen tyrosine kinase                                               NT_008470.18
  *KIF6*        0.8921                   0.9197         0.0276       0.8709         0.0258       Kinesin family member 6                                              NM_145027.3
  *MC1R*        0.8914                   0.9758         0.0844       0.9632         0.0365       Melanocortin 1 receptor                                              NM_002386.2
  *SLC16A5*     0.8911                   0.9846         0.0935       0.9538         0.0297       Solute carrier family 16; member 5                                   NM_004695.2
  *LRRC56*      0.8893                   0.9552         0.0658       0.9305         0.0664       Hypothetical protein LOC115399                                       NM_198075.1
  *SYTL1*       0.8890                   0.9215         0.0325       0.8721         0.0337       Synaptotagmin‐like 1                                                 NM_032872.1
  *EPHX2*       0.8886                   0.9217         0.0331       0.9083         0.0357       Epoxide hydrolase 2; cytoplasmic                                     NM_001979.4
  *SLC44A2*     0.8838                   0.9691         0.0854       0.9538         0.0297       CTL2 protein                                                         NM_020428.2
  *TMEM58*      0.8830                   0.9340         0.0510       0.9219         0.0393       Transmembrane protein 58                                             NM_198149.1
  *AARSD1*      0.8817                   0.9436         0.0619       0.9001         0.0364       Hypothetical protein LOC80755                                        NM_025267.2
  *CCND1*       0.8793                   0.9226         0.0432       0.8217         0.0349       Cyclin D1                                                            NM_053056.1
  *GRB7*        0.8777                   0.9499         0.0722       0.9036         0.1166       Growth factor receptor‐bound protein 7                               NM_005310.2
  *CLSTN1*      0.8743                   0.9028         0.0285       0.8493         0.0249       Calsyntenin 1 isoform 2                                              NM_014944.3

Methylation values for each CpG locus are expressed as a *β*‐value. Difference in KMX(−) − P(−): *β*‐value for K562/MX2 cells minus *β*‐value for K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(−). Beta: *β*‐value for K562/MX2 cells without 5‐Aza‐2′‐deoxycytidine treatment.

P(−). Beta: *β*‐value for K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(+). Beta: *β*‐value for K562/MX2 cells with 5‐Aza‐2′‐deoxycytidine treatment.

P(+). Beta: *β*‐value for K562/P cells with 5‐Aza‐2′‐deoxycytidine treatment.
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###### 

Methylation profile in K562/MX2 cells and K562/P cells. List of 30 highly methylated genes in K562/P cells compared to K562/MX2 cells

  Gene symbol   Difference KMX(−)‐P(−)   KMX(−). Beta   P(−).Beta   KMX(+). Beta   P(+).Beta   Description                                                                GenBank accession
  ------------- ------------------------ -------------- ----------- -------------- ----------- -------------------------------------------------------------------------- -------------------
  *FLJ14166*    −0.9012                  0.0366         0.9378      0.0288         0.9418      Hypothetical protein LOC79616                                              NM_024565.4
  *PAPPA*       −0.8892                  0.0386         0.9279      0.0414         0.9397      Pregnancy‐associated plasma protein A preproprotein                        NM_002581.3
  *PLOD2*       −0.8723                  0.0240         0.8963      0.0224         0.9177      Procollagen‐lysine; 2‐oxoglutarate 5‐dioxygenase 2 isoform a precursor     NM_182943.2
  *KIT*         −0.8634                  0.0489         0.9123      0.0382         0.8964      V‐kit Hardy--Zuckerman 4 feline sarcoma viral oncogene homolog precursor   NM_000222.1
  *EPHB3*       −0.8384                  0.1107         0.9491      0.1378         0.9605      Ephrin receptor EphB3 precursor                                            NM_004443.3
  *TOLLIP*      −0.8312                  0.0787         0.9099      0.0645         0.9028      Toll interacting protein                                                   NM_019009.2
  *CMKLR1*      −0.8311                  0.0457         0.8769      0.0488         0.8738      Chemokine‐like receptor 1                                                  NM_004072.1
  *PLK2*        −0.8198                  0.0780         0.8978      0.1627         0.9172      Polo‐like kinase 2                                                         NM_006622.1
  *TUBB6*       −0.8149                  0.1164         0.9313      0.1080         0.9435      Tubulin; beta 6                                                            NM_032525.1
  *IMPACT*      −0.8127                  0.0839         0.8966      0.0642         0.8878      Impact homolog                                                             NM_018439.1
  *HMGB3*       −0.8088                  0.0302         0.8391      0.0455         0.8161      High‐mobility group box 3                                                  NM_005342.2
  *GAS1*        −0.7955                  0.0544         0.8500      0.0566         0.8367      Growth arrest‐specific 1                                                   NM_002048.1
  *NRP2*        −0.7911                  0.0467         0.8378      0.0877         0.8919      Neuropilin 2 isoform 2 precursor                                           NM_003872.2
  *ONECUT1*     −0.7902                  0.1143         0.9045      0.0799         0.9279      One cut domain; family member 1                                            NM_004498.1
  *FLJ32130*    −0.7772                  0.0316         0.8088      0.0699         0.8098      Hypothetical protein LOC146540                                             NM_152458.4
  *PAM*         −0.7719                  0.0897         0.8616      0.0783         0.8202      Peptidylglycine alpha‐amidating monooxygenase isoform b; preproprotein     
  *PSD4*        −0.7697                  0.1044         0.8742      0.0925         0.8898      Pleckstrin and Sec7 domain containing 4                                    NM_012455.2
  *DNAJC6*      −0.7696                  0.1047         0.8742      0.0824         0.8941      DnaJ (Hsp40) homolog; subfamily C; member 6                                NM_014787.2
  *C6orf145*    −0.7690                  0.0152         0.7842      0.0191         0.8368      Hypothetical protein LOC221749                                             NM_183373.2
  *SLC16A10*    −0.7599                  0.0236         0.7835      0.0199         0.8055      Solute carrier family 16; member 10                                        NM_018593.3
  *ADCY9*       −0.7540                  0.0482         0.8023      0.0681         0.8739      Adenylate cyclase 9                                                        NM_001116.2
  *C1orf111*    −0.7478                  0.1083         0.8561      0.0516         0.8136      Hypothetical protein LOC284680                                             NM_182581.1
  *BCAS4*       −0.7350                  0.0243         0.7593      0.0374         0.6988      Breast carcinoma amplified sequence 4 isoform c                            NM_001010974.1
  *DNAI1*       −0.7336                  0.0525         0.7862      0.0470         0.8133      Dynein; axonemal; intermediate polypeptide 1                               NM_012144.2
  *SOX3*        −0.7334                  0.1791         0.9125      0.1547         0.8720      SRY (sex determining region Y)‐box 3                                       NM_005634.2
  *COBLL1*      −0.7317                  0.0314         0.7631      0.0209         0.8136      COBL‐like 1                                                                NM_014900.3
  *LOC253012*   −0.7124                  0.0638         0.7763      0.0467         0.8106      Hypothetical protein LOC253012 isoform 2                                   NM_198151.1
  *PROKR1*      −0.7018                  0.0871         0.7889      0.0719         0.8314      G protein‐coupled receptor 73                                              NM_138964.2
  *JAKMIP1*     −0.7013                  0.0486         0.7499      0.0449         0.8045      Multiple coiled‐coil GABABR1‐binding protein                               NM_144720.2
  *TSPAN18*     −0.6900                  0.1457         0.8357      0.1431         0.8207      Tetraspanin 18 isoform 2                                                   NM_130783.2

Methylation values for each CpG locus are expressed as a *β*‐value. Difference in KMX(−) − P(−): *β*‐value for K562/MX2 cells minus *β*‐value for K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(−). AVG Beta: *β*‐value for K562/MX2 cells without 5‐Aza‐2′‐deoxycytidine treatment.

P(−). AVG Beta: *β*‐value for K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(+). AVG Beta: *β*‐value for K562/MX2 cells with 5‐Aza‐2′‐deoxycytidine treatment.

P(+). AVG Beta: *β*‐value for K562/P cells with 5‐Aza‐2′‐deoxycytidine treatment.
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Gene expression patterns in drug‐sensitive and ‐resistant leukemic cells {#prp2285-sec-0025}
------------------------------------------------------------------------

After filtering, 22,409 genes were eligible for statistical analysis. The analysis identified 10,515 genes as differentially expressed between MX2‐sensitive and ‐resistant leukemia cells. Of these, 4896 showed higher expression, and 5619 showed lower expression in the drug‐resistant leukemia cells compared with those genes in the parent cells (Tables [4](#prp2285-tbl-0004){ref-type="table-wrap"}, [5](#prp2285-tbl-0005){ref-type="table-wrap"}). Lists of all expression profiles including full gene names and accession numbers are shown in Table S2. 5‐Aza‐2′‐deoxycytidine treatment induced changes in the expression of a few genes including an increase in low‐expression genes in K562/MX2 cells, but expression of most genes was not changed (Table [4](#prp2285-tbl-0004){ref-type="table-wrap"}, [5](#prp2285-tbl-0005){ref-type="table-wrap"}).

###### 

Expression profile in K562/MX2 cells and K562/P cells. List of highly expressed genes in K562/P cells compared to K562/MX2 cells

  Gene Symbol   Fold change (\[KMX−\]/\[P−\])   KMX(‐) Signal (normalized)   P(−) Signal (normalized)   KMX(+) Signal (normalized)   P(+) Signal (normalized)   Description                                                                                       Entrez Gene ID   Genbank accession
  ------------- ------------------------------- ---------------------------- -------------------------- ---------------------------- -------------------------- ------------------------------------------------------------------------------------------------- ---------------- -------------------
  *CTAG1A*      1/804.040                       18.9461                      15233.4490                 44.4236                      98.8608                    *Homo sapiens* cancer/testis antigen 1A (CTAG1A), mRNA                                            246100           NM_139250
  *DLK1*        1/676.138                       110.0428                     74404.1773                 119.4851                     72983.7166                 *Homo sapiens* delta‐like 1 homolog (Drosophila) (DLK1), mRNA                                     8788             NM_003836
  *VCX3A*       1/329.081                       34.8629                      11472.7370                 158.0995                     8514.7709                  *Homo sapiens* variable charge, X‐linked 3A (VCX3A), mRNA                                         51481            NM_016379
  *XAGE1A*      1/304.000                       111.6045                     33927.7938                 159.4567                     32875.3584                 *Homo sapiens* X antigen family, member 1A (XAGE1A), transcript variant a, mRNA                   653219           NM_001097592
  *VCX*         1/280.399                       27.8574                      7811.1865                  98.0080                      6299.8074                  *Homo sapiens* variable charge, X‐linked (VCX), mRNA                                              26609            NM_013452
  *VCX2*        1/279.433                       22.2797                      6225.7115                  101.9774                     5343.0137                  *Homo sapiens* variable charge, X‐linked 2 (VCX2), mRNA                                           51480            NM_016378
  *FHL2*        1/202.499                       35.0010                      7087.6714                  28.0545                      6380.1560                  *Homo sapiens* four and a half LIM domains 2 (FHL2), transcript variant 5, mRNA                   2274             NM_001039492
  *BEX4*        1/201.518                       20.8857                      4208.8693                  20.1313                      4470.3064                  *Homo sapiens* brain expressed, X‐linked 4 (BEX4), mRNA                                           56271            NM_001127688
  *HCLS1*       1/170.605                       62.1245                      10598.7536                 166.5296                     9431.3528                  *Homo sapiens* hematopoietic cell‐specific Lyn substrate 1 (HCLS1), mRNA                          3059             NM_005335
  *UCA1*        1/162.611                       52.8277                      8590.4024                  45.0836                      6804.6158                  *Homo sapiens* urothelial cancer associated 1 (nonprotein coding) (UCA1), noncoding RNA           652995           NR_015379
  *IFITM2*      1/150.728                       69.2778                      10442.1126                 41.0087                      9673.5787                  *Homo sapiens* interferon induced transmembrane protein 2 (1‐8D) (IFITM2), mRNA                   10581            NM_006435
  *CYB5A*       1/136.984                       53.3125                      7302.9771                  27.7678                      7909.5779                  *Homo sapiens* cytochrome b5 type A (microsomal) (CYB5A), transcript variant 2, mRNA              1528             NM_001914
  *GPR68*       1/135.231                       37.0398                      5008.9309                  15.6715                      5059.3734                  *Homo sapiens* G protein‐coupled receptor 68 (GPR68), mRNA                                        8111             NM_003485
  *CD24*        1/118.205                       63.0017                      7447.1309                  52.7524                      8239.4025                  *Homo sapiens* CD24 signal transducer mRNA, complete cds and 3′ region.                           1E+08            L33930
  *KIAA1324L*   1/116.956                       19.5615                      2287.8536                  26.6255                      2145.0269                  *Homo sapiens* KIAA1324‐like (KIAA1324L), transcript variant 2, mRNA                              222223           NM_152748
  *MAGEC1*      1/90.8075                       49.9079                      4532.0090                  105.6107                     4763.7946                  *Homo sapiens* melanoma antigen family C, 1 (MAGEC1), mRNA                                        9947             NM_005462
  *LAPTM5*      1/89.9161                       57.8335                      5200.1625                  46.0495                      6055.6957                  *Homo sapiens* lysosomal protein transmembrane 5 (LAPTM5), mRNA                                   7805             NM_006762
  *PAGE1*       1/88.9132                       18.0740                      1607.0165                  20.9886                      1928.6839                  *Homo sapiens* P antigen family, member 1 (prostate associated) (PAGE1), mRNA                     8712             NM_003785
  *CD33*        1/85.8366                       22.5623                      1936.6734                  15.1992                      1370.6828                  *Homo sapiens* CD33 molecule (CD33), transcript variant 1, mRNA                                   945              NM_001772
  *APOE*        1/85.4381                       328.2242                     28042.8431                 371.4469                     13980.5646                 *Homo sapiens* apolipoprotein E (APOE), mRNA                                                      348              NM_000041
  *PLCD1*       1/85.1325                       75.8706                      6459.0488                  90.9223                      6264.9575                  *Homo sapiens* phospholipase C, delta 1 (PLCD1), transcript variant 2, mRNA                       5333             NM_006225
  *CD86*        1/83.0913                       108.8506                     9044.5437                  28.5954                      271.0742                   *Homo sapiens* CD86 molecule (CD86), transcript variant 2, mRNA                                   942              NM_006889
  *HMBOX1*      1/75.5381                       63.1101                      4767.2217                  19.9192                      117.0972                   Homeobox containing 1                                                                             79618            
                1/74.9294                       33.2111                      2488.4885                  31.8588                      1932.3772                  1EA8_A chain A, apolipoprotein E3 22 kd fragment Lys146glu mutant.                                                 BU194531
  *VIL1*        1/74.6514                       25.1293                      1875.9400                  40.8610                      2293.2978                  *Homo sapiens* villin 1 (VIL1), mRNA                                                              7429             NM_007127
  *FERMT3*      1/72.2681                       27.4911                      1986.7312                  71.7283                      2664.9782                  *Homo sapiens* fermitin family homolog 3 (Drosophila) (FERMT3), transcript variant URP2LF, mRNA   83706            NM_178443
                1/67.7961                       60.9207                      4130.1873                                                                          *Homo sapiens* cDNA clone IMAGE:277235 5′, mRNA sequence                                                           N47124

Consider "italicizing *Homo sapiens*" in the tables.

Normalized values for each gene are shown.

Fold change (\[KMX−\]/\[P−\]): Normalized value in K562/MX2 cells divided by normalized value in K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(−) Signal (normalized): Normalized value in K562/MX2 cells without 5‐Aza‐2′‐deoxycytidine treatment.

P(−) Signal (normalized): Normalized value in K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(+) Signal (normalized): Normalized value in K562/MX2 cells with 5‐Aza‐2′‐deoxycytidine treatment.

P(+) Signal (normalized): Normalized value in K562/P cells with 5‐Aza‐2′‐deoxycytidine treatment.
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###### 

Expression profile in K562/MX2 cells and K562/P cells. List of highly expressed genes in K562/MX2 cells compared to K562/P cells

  Gene symbol   Fold change (\[KMX−\]/\[P−\])   KMX(−) Signal (normalized)   P(−) Signal (normalized)   KMX(+) Signal (normalized)   P(+) Signal (normalized)   Description                                                                                                              Entrez GeneID   Genbank accession
  ------------- ------------------------------- ---------------------------- -------------------------- ---------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------- -------------------
  *HBB*         258.9561                        53109.6352                   205.0914                   61532.7564                   234.5827                   *Homo sapiens* hemoglobin, beta (HBB), mRNA                                                                              3043            NM_000518
  *PLAT*        77.6454                         3227.8347                    41.5715                    2953.7541                    35.6801                    *Homo sapiens* plasminogen activator, tissue (PLAT), transcript variant 1, mRNA                                          5327            NM_000930
                72.2131                         4016.1516                    55.6153                    1469.0889                    52.5098                    BF213738 601847628F1 NIH_MGC_55 *Homo sapiens* cDNA clone IMAGE:4078519 5′, mRNA sequence                                                BF213738
  *CLEC2B*      66.8582                         3750.5358                    56.0969                    1372.3312                    58.6276                    *Homo sapiens* C‐type lectin domain family 2, member B (CLEC2B), mRNA                                                    9976            NM_005127
  *CXCL1*       64.9437                         2178.4647                    33.5439                    630.2581                     45.0387                    *Homo sapiens* chemokine (C‐X‐C motif) ligand 1 (melanoma growth stimulating activity, alpha) (CXCL1), mRNA              2919            NM_001511
  *S100A10*     46.6281                         14773.7249                   316.8413                   7658.6691                    352.0523                   *Homo sapiens* S100 calcium binding protein A10 (S100A10), mRNA                                                          6281            NM_002966
  *EMILIN2*     46.4009                         16469.0418                   354.9296                   9837.7386                    371.1331                   *Homo sapiens* elastin microfibril interfacer 2 (EMILIN2), mRNA                                                          84034           NM_032048
  *PPFIBP1*     45.6525                         1550.9474                    33.9729                    645.4800                     26.4176                    *Homo sapiens* PTPRF interacting protein, binding protein 1 (liprin beta 1) (PPFIBP1), transcript variant 1, mRNA        8496            NM_003622
  *COL6A1*      43.9149                         1951.9319                    44.4480                    1941.1771                    37.1725                    *Homo sapiens* collagen, type VI, alpha 1 (COL6A1), mRNA                                                                 1291            NM_001848
  *IL8*         43.4885                         2921.1090                    67.1697                    815.9359                     65.7085                    *Homo sapiens* interleukin 8 (IL8), mRNA                                                                                 3576            NM_000584
  *BATF3*       41.7773                         5358.6282                    128.2666                   2401.9560                    140.0571                   *Homo sapiens* basic leucine zipper transcription factor, ATF‐like 3 (BATF3), mRNA                                       55509           NM_018664
  *PGLYRP4*     41.3142                         1049.9370                    25.4135                    721.4657                     19.6105                    *Homo sapiens* peptidoglycan recognition protein 4 (PGLYRP4), mRNA                                                       57115           NM_020393
  *FN1*         40.5872                         1469.2060                    36.1987                    2108.7846                    57.9448                    *Homo sapiens* fibronectin 1 (FN1), transcript variant 1, mRNA                                                           2335            NM_212482
  *OSBPL6*      33.8573                         1769.1553                    52.2533                    1159.4035                    65.3581                    Oxysterol binding protein‐like 6                                                                                         114880          AK123248
  *ZDHHC11*     32.7875                         1003.1447                    30.5954                    1332.7551                    42.2168                    *Homo sapiens* zinc finger, DHHC‐type containing 11 (ZDHHC11), mRNA                                                      79844           NM_024786
  *TSPAN5*      32.5284                         1956.8982                    60.1596                    1961.2544                    106.6336                   *Homo sapiens* tetraspanin 5 (TSPAN5), mRNA                                                                              10098           NM_005723
  *TPST1*       29.7643                         1097.9944                    36.8900                    918.5039                     49.7456                    *Homo sapiens* tyrosylprotein sulfotransferase 1 (TPST1), mRNA                                                           8460            NM_003596
  *CTSL2*       28.0364                         3720.2736                    132.6945                   2890.063                     135.4341                   *Homo sapiens* cathepsin L2 (CTSL2), mRNA                                                                                1515            NM_001333
  *PHLDA1*      27.7600                         5847.4504                    210.6430                   2267.6291                    92.4228                    *Homo sapiens* pleckstrin homology‐like domain, family A, member 1 (PHLDA1), mRNA                                        22822           NM_007350
  *C20orf56*    27.7375                         2084.2000                    75.1403                    1494.8821                    85.9847                    *Homo sapiens* chromosome 20 open reading frame 56 (C20orf56), noncoding RNA                                             140828          NR_001558
  *PLOD2*       26.9148                         1185.7967                    44.0574                    1011.9656                    30.4028                    *Homo sapiens* procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 2 (PLOD2), transcript variant 1, mRNA                    5352            NM_182943
  *SLC44A1*     26.5518                         3707.7802                    139.6434                   973.0105                     61.0888                    *Homo sapiens* solute carrier family 44, member 1 (SLC44A1), mRNA                                                        23446           NM_080546
  *BACH2*       25.9313                         605.3930                     23.3461                    321.7125                     25.6866                    *Homo sapiens* BTB and CNC homology 1, basic leucine zipper transcription factor 2 (BACH2), transcript variant 1, mRNA   60468           NM_021813
  *HBD*         24.9633                         8707.2836                    348.8031                   33730.3461                   316.6115                   *Homo sapiens* hemoglobin, delta (HBD), mRNA                                                                             3045            NM_000519

Normalized values for each gene are shown.

Fold change (\[KMX−\]/\[P−\]): Normalized value in K562/MX2 cells divided by normalized value in K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(−) Signal (normalized): Normalized value in K562/MX2 cells without 5‐Aza‐2′‐deoxycytidine treatment.

P(−) Signal (normalized): Normalized value in K562/P cells without 5‐Aza‐2′‐deoxycytidine treatment.

KMX(+) Signal (normalized): Normalized value in K562/MX2 cells with 5‐Aza‐2′‐deoxycytidine treatment.

P(+) Signal (normalized): Normalized value in K562/P cells with 5‐Aza‐2′‐deoxycytidine treatment.
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Integrated methyl array data and expression array data {#prp2285-sec-0026}
------------------------------------------------------

Next, we integrated the data from the methyl array and expression array to identify genes with strong methylation‐specific changes in expression after quantile normalization. After integration, 9596 genes were eligible for further analysis. These genes were classified into four groups (hypermethylated with lower expression, hypermethylated with higher expression, hypomethylated with higher expression, hypomethylated with lower expression). We identified 326 genes with hypermethylation and lower expression in K562/MX2 cells (Table S3A), 173 genes with hypermethylation and higher expression in K562/MX2 cells (Table S3B), 71 genes with hypomethylation and higher expression in K562/MX2 cells (Table S3C), and 61 genes with hypomethylation and lower expression in K562/MX2 cells (Table S3D).

GO analysis in drug‐sensitive and ‐resistant leukemic cells {#prp2285-sec-0027}
-----------------------------------------------------------

GO analysis was performed using the dataset for 631 genes with either significantly higher or lower expression combined with higher or lower methylation in drug‐resistant leukemia cells (K562/MX2) compared with drug‐sensitive leukemia cells (K562/P) (Table S4A). In K562/MX2 cells that responded poorly to MX2, etoposide, and doxorubicin, selective enrichment of genes with significantly altered expression and methylation was found in ontology categories related to the response to stimuli, gene silencing, the extracellular region, and the immune response (Table [6](#prp2285-tbl-0006){ref-type="table-wrap"}, Table S4A, B). The methylation and expression status of each gene indicated that half of the genes were highly methylated with lower expression in resistant cells (Table S4B).

###### 

Analysis of 30 significant GO terms

  GO identifier   GO term                                              Ontology             \#Hits in group   Group size   \#Hits expected   *P* value
  --------------- ---------------------------------------------------- -------------------- ----------------- ------------ ----------------- -------------
  GO:0050896      Response to stimulus                                 Biological process   244               5306         186               1.77776E‐06
  GO:0070918      Production of small RNA involved in gene silencing   Biological process   62                876          31                2.98838E‐05
  GO:0031047      Gene silencing by RNA                                Biological process   62                885          31                3.07121E‐05
  GO:0005576      Extracellular region                                 Cellular component   88                1437         51                3.52275E‐05
  GO:0031050      dsRNA fragmentation                                  Biological process   62                876          31                3.73548E‐05
  GO:0048583      Regulation of response to stimulus                   Biological process   62                871          31                4.05668E‐05
  GO:0070920      Regulation of production of small RNA involved in    Biological process   62                871          31                6.08503E‐05
  GO:0043331      Response to dsRNA                                    Biological process   63                878          31                7.05792E‐05
  GO:0016458      Gene silencing                                       Biological process   64                962          34                0.000104926
  GO:0016020      Membrane                                             Cellular component   222               5069         178               0.000231564
  GO:0002376      Immune system process                                Biological process   104               1892         67                0.000282245
  GO:0005886      Plasma membrane                                      Cellular component   168               3486         123               0.000335645
  GO:0070887      Cellular response to chemical stimulus               Biological process   67                1070         38                0.000343859
  GO:0006955      Immune response                                      Biological process   73                1208         43                0.000359805
  GO:0042221      Response to chemical stimulus                        Biological process   162               3330         117               0.000378179
  GO:0032501      Multicellular organismal process                     Biological process   254               6016         211               0.000403796
  GO:0006952      Defense response                                     Biological process   71                1182         42                0.000572204
  GO:0005737      Cytoplasm                                            Cellular component   233               5640         198               0.00324465
  GO:0048518      Positive regulation of biological process            Biological process   157               3363         118               0.00379661
  GO:0050776      Regulation of immune response                        Biological process   30                384          14                0.00390334
  GO:0009986      Cell surface                                         Cellular component   23                260          10                0.00402714
  GO:0046649      Lymphocyte activation                                Biological process   37                525          19                0.00417652
  GO:0042110      T‐cell activation                                    Biological process   29                372          14                0.00430733
  GO:0009611      Response to wounding                                 Biological process   62                1078         38                0.0060105
  GO:0046651      Lymphocyte proliferation                             Biological process   19                202          8                 0.0060727
  GO:0010033      Response to organic substance                        Biological process   94                1836         65                0.00627684
  GO:0044421      Extracellular region part                            Cellular component   55                925          33                0.00629094
  GO:0070661      Leukocyte proliferation                              Biological process   19                204          8                 0.00639204
  GO:0002697      Regulation of immune effector process                Biological process   18                185          7                 0.00653073
  GO:0032943      Mononuclear cell proliferation                       Biological process   19                204          8                 0.00664772

GO, Gene Ontology.

John Wiley & Sons, Ltd

Key node search {#prp2285-sec-0028}
---------------

Using the key node search, we found that p38*α* was an important factor in methylation‐related MX2 resistance.

Increased phosphorylated p38*α* protein in MX2‐resistant leukemia cells and decreased phosphorylated p38*α* protein after pretreatment with p38*α* MAPK inhibitors {#prp2285-sec-0029}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

We examined the expression levels of phosphorylated p38*α* protein in MX2‐resistant leukemia cells compared with sensitive parent cells (Fig. [1](#prp2285-fig-0001){ref-type="fig"}). Phosphorylated p38*α* protein was increased in MX2‐resistant cells compared to parent cells. The specific inhibitors of p38 MAPK, SB203580 and SB202190, effectively decreased the levels of phosphorylated p38*α* protein in MX2‐resistant leukemia cells (K562/MX2, BALL/MX2) (Fig. [1](#prp2285-fig-0001){ref-type="fig"}).

![Increased phosphorylated p38*α* protein in MX2‐resistant leukemia cells and decreased phosphorylated p38*α* protein after pretreatment with p38*α* MAPK inhibitors. BALL/P, BALL/MX2, K562/P, and K562/MX2 cells were pretreated with or without SB202190, SB203580, or SB202474 for 30 min, and then phosphorylated p38 protein expression was measured. Phosphorylated p38*α* protein was increased in MX2‐resistant cells compared to parent cells. Specific inhibitors of p38 MAPK,SB203580 and SB202190, effectively decreased phosphorylated p38*α* protein in MX2‐resistant leukemia cells (K562/MX2, BALL/MX2). Representative data from three independent experiments are shown. MAPK, mitogen‐activated protein kinase.](PRP2-5-e00285-g001){#prp2285-fig-0001}

Increased p38 kinase activity in MX2‐resistant leukemia cells and decreased p38 kinase activity after pretreatment with p38 MAPK inhibitors {#prp2285-sec-0030}
-------------------------------------------------------------------------------------------------------------------------------------------

We next examined the p38 kinase activity in MX2‐resistant leukemia cells compared with sensitive parent cells (Fig. [2](#prp2285-fig-0002){ref-type="fig"}A and B). The p38 kinase activity was increased in MX2‐resistant cells compared to parent cells. Using specific inhibitors of p38 MAPK, SB203580 and SB202190, effectively decreased the p38 kinase activity in MX2‐resistant leukemia cells (K562/MX2, BALL/MX2), but SB202474 (negative control) did not decrease the activity (Fig. [2](#prp2285-fig-0002){ref-type="fig"}A and B).

![p38 kinase activity in BALL/P, BALL/MX2, K562/P, and K562/MX2 cells with or without pretreatment with SB202190, SB203580, or SB202474. BALL/P, BALL/MX2, K562/P, and K562/MX2 cells were pretreated with or without SB202190, SB203580, or SB202474 for 30 min, and then p38 kinase activity was measured. A significant increase in p38 kinase activity was observed in BALL/MX2 and K562/MX2 cells compared with BALL/P and K562/P cells, respectively. Treatment with SB202190 or SB203580 significantly decreased p38 kinase activity in BALL/MX2 and K562/MX2 cells compared with untreated BALL/MX2 and K562/MX2 cells, respectively. Data are the means ± standard deviation from three independent experiments. *P* \< 0.05: BALL/MX2(−) versus BALL/MX2+ SB202190. *P* \< 0.01: BALL/MX2(−) versus BALL/MX2+ SB203580. *P* \< 0.005: BALL/MX2+ SB202474 versus BALL/MX2 +  SB202190. *P* \< 0.02: BALL/MX2+ SB202474 versus BALL/MX2+ SB203580. *P* \< 0.005: K562/MX2(−) versus K562/MX2 +  SB202190. *P* \< 0.04: K562/MX2(−) versus K562/MX2 +  SB203580. *P* \< 0.005: K562/MX2 +  SB202474 versus K562/MX2 +  SB202190. *P* \< 0.001: K562/MX2 +  SB202474 versus K562/MX2 +  SB203580.](PRP2-5-e00285-g002){#prp2285-fig-0002}

Increased cytotoxicity with MX2 in MX2‐resistant leukemia cells following pretreatment with p38 MAPK inhibitors {#prp2285-sec-0031}
---------------------------------------------------------------------------------------------------------------

First, we determined the optimal concentration of SB202190, SB203580, and SB202474 in K562 and BALL cells. Leukemia cells were incubated with various concentrations of these drugs for 72 hours, and the viability was measured. The IC50 values in BALL/P cells for SB202190, SB203580, and SB202474 were 400 ± 123 *μ*mol/L, 200 ± 6 *μ*mol/L, and 380 ± 88 *μ*mol/L, and in BALL/MX2 cells were 1200 ± 320 *μ*mol/L, 190 ± 67 *μ*mol/L, and 700 ± 267 *μ*mol/L, respectively. The IC50 values in K562/P cells were 560 ± 160 *μ*mol/L, 240 ± 62 *μ*mol/L, and 980 ± 80 *μ*mol/L, and in K562/MX2 cells were 250 ± 57 *μ*mol/L, 220 ± 35 *μ*mol/L, and 1200 ± 378*μ*mol/L, respectively. Based on these values and a previous report (Planchard et al. [2012](#prp2285-bib-0011){ref-type="ref"}), we used 10 *μ*mol/L SB202190, 10 *μ*mol/L SB203580, and 10 *μ*mol/L SB202474 as a pretreatment for 30 min. Then, various concentrations of MX2 were added, and the cells were cultured for 72 h. SB202190 or SB203580 pretreatment significantly increased the cytotoxicity of MX2 in BALL/MX2 cells and K562/MX2 cells, but not in parent cells (Fig. [3](#prp2285-fig-0003){ref-type="fig"}A and B). The combination index values of MX2 plus SB202190, SB203580, or SB202474 were 0.99, 1.08, and 1.08 in BALL/P cells, 0.06, 0.10, and 1.01 in BALL/MX2 cells, 1.18, 0.99, and 0.92 in K562/P cells, and 0.18, 0.18, and 1.51 in K562/MX2 cells, respectively. These results strongly suggested that MX2 synergistically acted with SB202190 or SB203580 in MX2‐resistant cells, but MX2 did not act synergistically with SB202474 (negative control).

![Cytotoxicity of MX2 in BALL/P, BALL/MX2, K562/P, and K562/MX2 cells with or without pretreatment with SB202190, SB203580, or SB202474. BALL/P, BALL/MX2, K562/P, and K562/MX2 cells were pretreated with or without SB202190, SB203580, or SB202474 for 30 min, and then treated with or without various concentrations of MX2 for 72 h. We showed graph at the 1 as without inhibitors and MX2 treatment. Slight decreased viability in BALL and K562 cells treated with SB202190, SB203580 without MX2 treatment. A significant increase in cytotoxicity with MX2 was observed in BALL/MX2 and K562/MX2 cells pretreated with SB202190 or SB203580. Data are the means ± standard deviation from three independent experiments.](PRP2-5-e00285-g003){#prp2285-fig-0003}

Increased p38*α* mRNA expression in MX2‐resistant leukemia cells and decreased p38*α* mRNA expression after pretreatment with siRNAs to knock down p38*α* MAPK expression {#prp2285-sec-0032}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next examined the p38*α* mRNA expression in MX2‐resistant leukemia cells compared with sensitive parent cells (Fig. [4](#prp2285-fig-0004){ref-type="fig"}). The p38*α* mRNA expression was increased in MX2‐resistant cells compared to parent cells. Using siRNAs (siRNA1, 2, 3) to knock down p38*α* effectively decreased the p38*α* mRNA and protein expression in MX2‐resistant leukemia cells (K562/MX2, BALL/MX2) (Fig. [4](#prp2285-fig-0004){ref-type="fig"}A--D).

![Increased p38*α* mRNA expression in MX2‐resistant leukemia cells and decreased p38*α* mRNA and protein expression after pretreatment with siRNAs to knock down p38*α* MAPK. (A and B) p38*α* mRNA expression was measured in MX2‐resistant leukemia cells and sensitive parent cells. p38*α* mRNA expression was increased in MX2‐resistant cells compared to parent cells. siRNAs (siRNA1, 2, 3) to knock down p38*α* effectively decreased p38*α* mRNA expression in MX2‐resistant leukemia cells (BALL/MX2(A), K562/MX2(B)). The data shown are from six independent experiments. *P* \< 0.05: BALL/P versus BALL/MX2. *P* \< 0.02: BALL/MX2(−) versus BALL/MX2 +  siRNA. *P* \< 0.03: BALL/MX2(−) versus BALL/MX2 +  siRNA2. *P* \< 0.01: BALL/MX2(−) versus BALL/MX2 +  siRNA3. *P* \< 0.01: K562/P versus K562/MX2. *P* \< 0.01: K562/MX2(−) versus K562/MX2 +  siRNA. *P* \< 0.03: K562/MX2(−) versus K562/MX2 +  siRNA2. *P* \< 0.01: K562/MX2(−) versus K562/MX2 +  siRNA3. (C) and (D) p38*α* protein was investigated in MX2‐resistant leukemia cells and sensitive parent cells. siRNAs (siRNA1, 2, 3) to knock down p38*α* effectively decreased p38*α* protein expression in MX2‐resistant leukemia cells (BALL/MX2(C), K562/MX2(D)). The data shown are representative data from two independent experiments. MAPK, mitogen‐activated protein kinase.](PRP2-5-e00285-g004){#prp2285-fig-0004}

Increased cytotoxicity with MX2 in MX2‐resistant leukemia cells following pretreatment with siRNAs for p38*α* MAPK {#prp2285-sec-0033}
------------------------------------------------------------------------------------------------------------------

Pretreatment with siRNAs to knock down p38*α* mRNA expression significantly increased the cytotoxicity of MX2 in BALL/MX2 cells and K562/MX2 cells, but not in parent cells (Fig. [5](#prp2285-fig-0005){ref-type="fig"}). The combination index values of MX2 plus siRNA for knock down of p38*α* and negative control siRNA were 0.98, 0.96, and 0.99 for siRNA1, 2, 3, and 0.97 for negative control siRNA in BALL/P cells, 0.05, 0.04, and 0.08 for siRNA1, 2, 3, and 1.02 for negative control siRNA in BALL/MX2 cells, 0.98, 0.95, and 0.93 for siRNA1, 2, 3, and 0.95 for negative control siRNA in K562/P cells, and 0.15, 0.13, and 0.18 for siRNA1, 2, 3, and 0.97 for negative control siRNA in K562/MX2 cells, respectively. These results strongly suggested that MX2 synergistically acted with siRNAs in MX2‐resistant cells.

![Cytotoxicity of MX2 in BALL/P, BALL/MX2, K562/P, and K562/MX2 cells with or without pretreatment with siRNA. BALL/P, BALL/MX2, K562/P, and K562/MX2 cells were pretreated with or without siRNA for 30 min, and then treated with or without various concentrations of MX2 for 72 h. Slight decreased viability in BALL and K562 cells treated with siRNA1, 2, 3 without MX2 treatment. A significant increase in cytotoxicity with MX2 was observed in BALL/MX2 and K562/MX2 cells pretreated with siRNA1, 2, 3. Data are reported as the mean ± standard deviation from three independent experiments. (A): BALL. (B): K562.](PRP2-5-e00285-g005){#prp2285-fig-0005}

CpG islands in p38*α* might contribute to changes in expression in MX2‐resistant leukemia cell lines {#prp2285-sec-0034}
----------------------------------------------------------------------------------------------------

We measured the methylation status in the p38*α* gene by MSP analysis in BALL/P, BALL/MX2, K562/P, and K562/MX2 cells. MX2‐resistant cell lines showed more methylation in p38*α* gene (position 1951, 10992 in BALL and K562, 4618 in BALL, 13929 in K562) we examined, but some of CpG islands (position 4618 in K562, and 13929 in BALL) showed more methylation in parent cells (Fig. [6](#prp2285-fig-0006){ref-type="fig"}).

![Methylation status in p38*α* in BALL, K562 parent cells, and MX2‐resistant cells. Methylated and unmethylated p38*α* gene was evaluated by methylation‐specific PCR using qPCR. Relative ratio was calculated as the expression with methylated primers/expression with unmethylated primers in each cell lines. Data are averages from two independent experiments.](PRP2-5-e00285-g006){#prp2285-fig-0006}

Caspase activity with SB202190, SB203580, and MX2 increased in MX2‐resistance leukemia cells {#prp2285-sec-0035}
--------------------------------------------------------------------------------------------

Caspase 3 (and caspase 7) showed decreased proteolytic activity in MX2‐resistant cells and slightly increased proteolytic activity at 30‐min exposure with SB202190 and SB203580. And, marked enhanced proteolytic activity was shown at 1 h exposure with 2.5 nmol/L of MX2 in MX2‐resistant cell lines treated with SB202190 and SB203580. (Fig. [7](#prp2285-fig-0007){ref-type="fig"}A and B).

![Caspase activities in BALL, K562 parent cells, and MX2‐resistant cells treated SB201290, SB203570, SB202474, and MX2. A total quantity of 10 *μ*mol/L SB202190, 10 *μ*mol/L SB203580, and 10 *μ*mol/L SB202474 were pretreated for 30 min. Then, 2.5 nmol/L of MX2 were added and incubated for 1 h and then caspase 3/7 activity assays were performed. Data are averages from two independent experiments. (A): BALL. (B): K562.](PRP2-5-e00285-g007){#prp2285-fig-0007}

Discussion {#prp2285-sec-0036}
==========

Childhood leukemia is the most common childhood cancer. The majority of children can be cured with current therapies, although around 20% of children relapse, and their outcome remains dismal. Although reinduction regimens with higher doses of antileukemic drugs with or without stem cell transplantation are used to treat relapsed leukemia, the remission rate has not improved. Therefore, further dose intensification is not a viable option for improving outcomes, and other novel therapeutic options are necessary. Understanding the mechanism of drug resistance is essential prior to exploring new strategies against relapse. We previously reported that aberrant methylation of genes for key enzymes involved in drug metabolism is a novel mechanism of drug resistance (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}). Exploitation of the methodology for analyzing the methylation status throughout the entire genome and the development of statistical methods for large datasets have enabled exploration and new insight into epigenetics and drug resistance (Hogan et al. [2011](#prp2285-bib-0006){ref-type="ref"}). Here, we found novel mechanisms involving p38*α* in resistance to MX2 using high‐throughput methylation analysis of multiple CpG sites and GO and key node analyses.

Inhibition of p38 MAPK activation by pharmacological inhibitors increased the cytotoxicity of MX2 in MX2‐resistant leukemia cell lines, but not in MX2‐sensitive cell lines. Our results suggest that adding p38 MAPK inhibitors will decrease the resistance to MX2 in MX2‐resistant leukemia cell lines by partially decreasing p38 activity.

The p38 MAPK pathway, which was initially identified as playing a role in stress and the inflammatory response, has a tumor suppressor function as well. The p38 MAPK pathway suppresses tumorigenesis by controlling the cell cycle, cell differentiation, cell proliferation, oncogene‐induced and replicative senescence, contact inhibition, the DNA damage response, and induction of apoptosis. p38 MAP kinase also inhibits apoptosis in several types of cells, including multiple myeloma cells (Navas et al. [2006](#prp2285-bib-0010){ref-type="ref"}; Wen et al. [2008](#prp2285-bib-0018){ref-type="ref"}). p38 activation mediates tamoxifen resistance in estrogen receptor‐positive breast tumors (Gutierrez et al. [2005](#prp2285-bib-0005){ref-type="ref"}). p38 inhibition enhances the sensitivity of multiple myeloma cells to arsenic trioxide and bortezomib (Wen et al. [2010](#prp2285-bib-0019){ref-type="ref"}). However, the details of the mechanism of enhanced drug sensitivity remain unclear. Our current study is the first to show that cytotoxicity due to increased inhibition of p38 MAPK is related to aberrant methylation in drug‐resistant leukemia cells.

The gold standard of current treatment against relapsed or refractory leukemia is allogeneic stem cell transplantation. This treatment strategy is effective for patients in complete remission, but not in patients who have not achieved complete remission. Although increasing the dose of cytotoxic drugs increases the cure rate and the rate of complete remission in relapsed patients, the cure rate has recently reached a plateau. A novel strategy to achieve complete remission in relapsed patients is needed. We believe that epigenetics is a major mechanism of drug resistance (Asano et al. [2005](#prp2285-bib-0002){ref-type="ref"}; Yamanishi et al. [2015](#prp2285-bib-0020){ref-type="ref"}). We analyzed the genome‐wide methylation status in MX2‐resistant leukemia cells and found that p38*α* was a key enzyme in MX2‐related drug resistance. This strategy for finding the key enzyme from the viewpoint of epigenetic changes may be a powerful concept for exploring new drugs to combat drug resistance. A p38 inhibitor may be a novel candidate for leukemia treatment.

In conclusion, our study showed that the p38*α* signaling pathway is involved in MX2‐induced drug resistance. Inhibition of p38 MAPK restored the sensitivity to MX2 in MX2‐resistant leukemia cell lines. Thus, p38 inhibitors may provide new chemotherapeutic options for overcoming drug resistance in the treatment of cancer. Further studies on the mechanisms of p38 inhibitors in drug resistance and the development of effective p38‐specific antagonists with low toxicity are expected to improve the clinical effects of chemotherapy.
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